Halozyme Therapeutics | HALO - Créances Commerciales





Créances Commerciales Changement Date
Acadia Pharmaceuticals USD 148.38M 153K 2026-03
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
Alnylam Pharmaceuticals USD 883.96M 106.39M 2026-03
Amarin USD 126.83M 477K 2025-12
Amgen USD 9.14B 432M 2026-03
Baxter International USD 1.7B 310M 2026-03
Cara Therapeutics USD 2.24M 2.26M 2025-03
Cytokinetics USD 6.83M 10.94M 2026-03
DBV Technologies USD 15.97M 279K 2025-09
Eli Lilly USD 21.18B 1.02B 2026-03
Esperion Therapeutics USD 140.19M 21.21M 2025-12
Halozyme Therapeutics USD 457.99M 16.72M 2026-03
Intrexon USD 1.02M 559K 2024-06
Ionis Pharmaceuticals USD 74M 8M 2026-03
MannKind USD 28.14M 10.23M 2026-03
Nektar Therapeutics USD 1.78M 1.12M 2025-12
Pfizer USD 16.17B 332M 2026-03
Rigel Pharmaceuticals USD 28.9M 1.39M 2024-06
United Therapeutics USD 312M 38.2M 2026-03
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12